Neuren Pharmaceuticals Management
Management criteria checks 3/4
Neuren Pharmaceuticals' CEO is Jon Pilcher, appointed in May 2020, has a tenure of 4.5 years. total yearly compensation is A$1.36M, comprised of 40.2% salary and 59.8% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth A$4.92M. The average tenure of the management team and the board of directors is 4.4 years and 6.3 years respectively.
Key information
Jon Pilcher
Chief executive officer
AU$1.4m
Total compensation
| CEO salary percentage | 40.2% |
| CEO tenure | 4.5yrs |
| CEO ownership | 0.3% |
| Management average tenure | 4.4yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Nov 11
Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 08Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Oct 24Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | AU$117m |
| Mar 31 2024 | n/a | n/a | AU$137m |
| Dec 31 2023 | AU$1m | AU$549k | AU$157m |
| Sep 30 2023 | n/a | n/a | AU$106m |
| Jun 30 2023 | n/a | n/a | AU$55m |
| Mar 31 2023 | n/a | n/a | AU$28m |
| Dec 31 2022 | AU$546k | AU$396k | AU$184k |
| Sep 30 2022 | n/a | n/a | -AU$3m |
| Jun 30 2022 | n/a | n/a | -AU$7m |
| Mar 31 2022 | n/a | n/a | -AU$7m |
| Dec 31 2021 | AU$432k | AU$203k | -AU$8m |
Compensation vs Market: Jon's total compensation ($USD887.19K) is about average for companies of similar size in the Australian market ($USD1.11M).
Compensation vs Earnings: Jon's compensation has increased by more than 20% in the past year.
CEO
Jon Pilcher
4.5yrs
Tenure
AU$1,364,404
Compensation
Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA, FCA serves as Managing Director & Executive Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | 4.5yrs | AU$1.36m | 0.31% A$ 4.9m | |
| CFO & Company Secretary | 4.3yrs | no data | no data | |
| Chief Science Officer | 20.8yrs | no data | no data | |
| Vice President of Corporate Development | no data | no data | no data | |
| Chief Medical Officer | 2.3yrs | no data | no data |
4.4yrs
Average Tenure
Experienced Management: NEU's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | 3.4yrs | AU$1.36m | 0.31% A$ 4.9m | |
| Independent Non-Executive Director | 6.3yrs | AU$75.00k | 0.023% A$ 370.8k | |
| Independent Non-Executive Director | 6.3yrs | AU$75.00k | 0.023% A$ 366.7k | |
| Independent Non-Executive Chairman | 6.3yrs | AU$125.00k | 0.21% A$ 3.3m | |
| Independent Non-Executive Director | 1.7yrs | AU$62.50k | 0.017% A$ 264.6k |
6.3yrs
Average Tenure
Experienced Board: NEU's board of directors are considered experienced (6.3 years average tenure).